| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
| Asthenia | D001247 | 5 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Lymphoma, B-Cell | D016393 | 24 associated lipids |
| Breast Neoplasms | D001943 | 24 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Hyperplasia | D006965 | 34 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
| Leukemia, Myeloid | D007951 | 52 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Hurvitz SA et al. | Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. | 2013 | J. Clin. Oncol. | pmid:23382472 |
| Giordano SH et al. | Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. | 2014 | J. Clin. Oncol. | pmid:24799465 |
| Moore KN et al. | Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. | 2017 | J. Clin. Oncol. | pmid:28029313 |
| Force J et al. | Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine. | 2016 | J. Clin. Oncol. | pmid:24778392 |
| Krop IE et al. | Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. | 2010 | J. Clin. Oncol. | pmid:20421541 |
| Perez EA et al. | Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. | 2017 | J. Clin. Oncol. | pmid:28056202 |
| Hassan R et al. | Mesothelin Immunotherapy for Cancer: Ready for Prime Time? | 2016 | J. Clin. Oncol. | pmid:27863199 |
| Sandra K et al. | Multiple heart-cutting and comprehensive two-dimensional liquid chromatography hyphenated to mass spectrometry for the characterization of the antibody-drug conjugate ado-trastuzumab emtansine. | 2016 | J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. | pmid:27160547 |
| Fan Y et al. | Effects of modulation of pentose-phosphate pathway on biosynthesis of ansamitocins in Actinosynnema pretiosum. | 2016 | J. Biotechnol. | pmid:27173582 |
| Fan Y et al. | Process optimization with alternative carbon sources and modulation of secondary metabolism for enhanced ansamitocin P-3 production in Actinosynnema pretiosum. | 2014 | J. Biotechnol. | pmid:25456055 |
| Floss HG | Combinatorial biosynthesis--potential and problems. | 2006 | J. Biotechnol. | pmid:16414140 |
| Lin CM and Hamel E | Effects of inhibitors of tubulin polymerization on GTP hydrolysis. | 1981 | J. Biol. Chem. | pmid:6114958 |
| Roach MC and Ludueña RF | Different effects of tubulin ligands on the intrachain cross-linking of beta 1-tubulin. | 1984 | J. Biol. Chem. | pmid:6480599 |
| Bai RL et al. | Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. | 1990 | J. Biol. Chem. | pmid:2211617 |
| Bai RL et al. | Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. | 1991 | J. Biol. Chem. | pmid:1874739 |
| Hatano K et al. | Biosynthetic origin of aminobenzenoid nucleus (C7N-unit) of ansamitocin, a group of novel maytansinoid antibiotics. | 1982 | J. Antibiot. | pmid:7174527 |
| Tanida S et al. | Ansamitocin analogs from a mutant strain of Nocardia. I. Isolation of the mutant, fermentation and antimicrobial properties. | 1981 | J. Antibiot. | pmid:7275830 |
| Izawa M et al. | Ansamitocin analogs from a mutant strain of Nocardia. II. Isolation and structure. | 1981 | J. Antibiot. | pmid:7275831 |
| Tanida S et al. | Ansamitocins, maytansinoid antitumor antibiotics. Producing organism, fermentation, and antimicrobial activities. | 1980 | J. Antibiot. | pmid:7380728 |
| Nakahama K et al. | Microbial conversion of ansamitocin. | 1981 | J. Antibiot. | pmid:7333971 |
| Izawa M et al. | Demethylation of ansamitocins and related compounds. | 1981 | J. Antibiot. | pmid:7333972 |
| Izawa M et al. | Hydroxylation of ansamitocin P-3. | 1981 | J. Antibiot. | pmid:7333973 |
| Lu C et al. | A novel amide N-glycoside of ansamitocins from Actinosynnema pretiosum. | 2004 | J. Antibiot. | pmid:15303496 |
| Carroll BJ et al. | Identification of a set of genes involved in the formation of the substrate for the incorporation of the unusual "glycolate" chain extension unit in ansamitocin biosynthesis. | 2002 | J. Am. Chem. Soc. | pmid:11960423 |
| Moss SJ et al. | Identification of asm19 as an acyltransferase attaching the biologically essential ester side chain of ansamitocins using N-desmethyl-4,5-desepoxymaytansinol, not maytansinol, as its substrate. | 2002 | J. Am. Chem. Soc. | pmid:12047169 |
| Taft F et al. | Timing of the Delta(10,12)-Delta(11,13) double bond migration during ansamitocin biosynthesis in Actinosynnema pretiosum. | 2009 | J. Am. Chem. Soc. | pmid:19292483 |
| Spiteller P et al. | The post-polyketide synthase modification steps in the biosynthesis of the antitumor agent ansamitocin by Actinosynnema pretiosum. | 2003 | J. Am. Chem. Soc. | pmid:14624546 |
| Wenzel SC et al. | On the biosynthetic origin of methoxymalonyl-acyl carrier protein, the substrate for incorporation of "glycolate" units into ansamitocin and soraphen A. | 2006 | J. Am. Chem. Soc. | pmid:17076505 |
| Wang HH et al. | Tau overexpression inhibits cell apoptosis with the mechanisms involving multiple viability-related factors. | 2010 | J. Alzheimers Dis. | pmid:20413892 |
| Weiler D et al. | Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer. | 2015 | J Thorac Oncol | pmid:25789838 |
| Chuang JC et al. | ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. | 2017 | J Thorac Oncol | pmid:28167203 |
| Yao Y et al. | Preparative isolation and purification of anti-tumor agent ansamitocin P-3 from fermentation broth of Actinosynnema pretiosum using high-performance counter-current chromatography. | 2010 | J Sep Sci | pmid:20235129 |
| Gibiansky L and Gibiansky E | Target-mediated drug disposition model and its approximations for antibody-drug conjugates. | 2014 | J Pharmacokinet Pharmacodyn | pmid:24322877 |
| Haddish-Berhane N et al. | On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. | 2013 | J Pharmacokinet Pharmacodyn | pmid:23933716 |
| Jumbe NL et al. | Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. | 2010 | J Pharmacokinet Pharmacodyn | pmid:20424896 |
| Suchocki JA and Sneden AT | Characterization of decomposition products of maytansine. | 1987 | J Pharm Sci | pmid:11002812 |
| Wiggins B et al. | Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates. | 2015 | J Pharm Sci | pmid:25631158 |
| Lu SX et al. | Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy. | 2005 | J Pharm Sci | pmid:15729708 |
| Mohamed HE et al. | Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol. | 2018 | J Pharm Biomed Anal | pmid:29258046 |
| Liu Y et al. | LC-MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1). | 2017 | J Pharm Biomed Anal | pmid:28131055 |
| Iwamoto N et al. | LC-MS bioanalysis of Trastuzumab and released emtansine using nano-surface and molecular-orientation limited (nSMOL) proteolysis and liquid-liquid partition in plasma of Trastuzumab emtansine-treated breast cancer patients. | 2017 | J Pharm Biomed Anal | pmid:28648785 |
| Heudi O et al. | Quantitative analysis of maytansinoid (DM1) in human serum by on-line solid phase extraction coupled with liquid chromatography tandem mass spectrometry - Method validation and its application to clinical samples. | 2016 | J Pharm Biomed Anal | pmid:26771131 |
| Liu Z et al. | An API LC/MS/MS quantitation method for ansamitocin P-3 (AP3) and its preclinical pharmacokinetics. | 2004 | J Pharm Biomed Anal | pmid:15533675 |
| Shafaee MN et al. | Skin Necrosis After Ado-Trastuzumab Emtansine Extravasation. | 2017 | J Oncol Pract | pmid:28678590 |
| Baron JM et al. | Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. | 2015 | J Oncol Pharm Pract | pmid:24682654 |
| Parikh A et al. | Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. | 2017 | J Natl Compr Canc Netw | pmid:28040715 |
| Liu Z et al. | Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry. | 2005 | J Mass Spectrom | pmid:15674857 |
| Schönfeld K et al. | Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies. | 2017 | J Hematol Oncol | pmid:28077160 |
| Sibaud V et al. | T-DM1 extravasation: first description. | 2016 | J Eur Acad Dermatol Venereol | pmid:25879278 |
| Zhong P et al. | αβ Integrin-targeted reduction-sensitive micellar mertansine prodrug: Superb drug loading, enhanced stability, and effective inhibition of melanoma growth in vivo. | 2017 | J Control Release | pmid:27986551 |
| Gupta M et al. | Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. | 2012 | J Clin Pharmacol | pmid:21953571 |
| Wang C et al. | Chromatography-based methods for determining molar extinction coefficients of cytotoxic payload drugs and drug antibody ratios of antibody drug conjugates. | 2016 | J Chromatogr A | pmid:27286648 |
| Sendur MA et al. | Does trastuzumab-emtansine have better cardiac safety profile in contrast to trastuzumab? | 2013 Jul-Sep | J BUON | pmid:24065505 |
| Rebert CS et al. | Effects of vincristine, maytansine, and cis-platinum on behavioral and electrophysiological indices of neurotoxicity in the rat. | 1984 | J Appl Toxicol | pmid:6542922 |
| Lieberman P and Castells M | Desensitization to chemotherapeutic agents. | 2014 Jan-Feb | J Allergy Clin Immunol Pract | pmid:24565784 |
| Shah MH et al. | Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. | 2016 | Invest New Drugs | pmid:26961907 |
| Lapusan S et al. | Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. | 2012 | Invest New Drugs | pmid:21519855 |
| Zhang YG et al. | Nocardiopsis ansamitocini sp. nov., a new producer of ansamitocin P-3 of the genus Nocardiopsis. | 2016 | Int. J. Syst. Evol. Microbiol. | pmid:26486850 |
| Sauter A et al. | Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. | 2007 | Int. J. Oncol. | pmid:17332932 |
| Yu L et al. | Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model. | 2014 | Int. J. Gynecol. Cancer | pmid:24987913 |
| Takegawa N et al. | DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. | 2017 | Int. J. Cancer | pmid:28677116 |
| Ladino CA et al. | Folate-maytansinoids: target-selective drugs of low molecular weight. | 1997 | Int. J. Cancer | pmid:9399666 |
| Kim SB et al. | Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. | 2016 | Int. J. Cancer | pmid:27428671 |
| Mang Y et al. | Efficient elimination of CD103-expressing cells by anti-CD103 antibody drug conjugates in immunocompetent mice. | 2015 | Int. Immunopharmacol. | pmid:25467246 |
| Zhong P et al. | αβ integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo. | 2017 | Int J Nanomedicine | pmid:29138558 |
| Li Y et al. | EpCAM aptamer-functionalized polydopamine-coated mesoporous silica nanoparticles loaded with DM1 for targeted therapy in colorectal cancer. | 2017 | Int J Nanomedicine | pmid:28894364 |
| Janthur WD et al. | Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice. | 2012 | Int J Mol Sci | pmid:23443108 |
| Madden R et al. | Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
. | 2018 | Int J Clin Pharmacol Ther | pmid:29231164 |
| Watanabe J et al. | Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer. | In Vivo | pmid:28438884 | |
| Damodaran S and Olson EM | Targeting the human epidermal growth factor receptor 2 pathway in breast cancer. | 2012 | Hosp Pract (1995) | pmid:23299030 |
| Yeo W et al. | Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. | 2018 | Hong Kong Med J | pmid:29326401 |
| Drachman JG and Senter PD | Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer. | 2013 | Hematology Am Soc Hematol Educ Program | pmid:24319196 |
| Breakthrough breast cancer drug. Finally, some hope for women who've run out of options. | 2012 | Harv Health Lett | pmid:23243689 | |
| Moore KN et al. | Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. | 2018 | Gynecol. Oncol. | pmid:30093227 |
| Menderes G et al. | Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. | 2017 | Gynecol. Oncol. | pmid:28705408 |
| Menderes G et al. | SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. | 2017 | Gynecol. Oncol. | pmid:28473206 |
| Teplinsky E and Muggia F | Targeting HER2 in ovarian and uterine cancers: challenges and future directions. | 2014 | Gynecol. Oncol. | pmid:25220628 |
| Martin LP et al. | Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. | 2017 | Gynecol. Oncol. | pmid:28843653 |
| Carvajal-Hausdorf DE et al. | Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance. | 2017 | Gynecol. Oncol. | pmid:28196634 |
| Coussy F et al. | [New targeted therapies in breast cancer]. | 2014 | Gynecol Obstet Fertil | pmid:25442825 |
| Boku N | HER2-positive gastric cancer. | 2014 | Gastric Cancer | pmid:23563986 |
| Yabe N et al. | [A Case of Advanced Breast Cancer in Which Marked Improvement of Joint Pain Was Obtained with Stepwise Dose Reduction of Trastuzumab Emtansine (T-DM1)]. | 2015 | Gan To Kagaku Ryoho | pmid:26805183 |
| Noguchi E and Shimizu C | [T-DM1 and pertuzumab: emerging anti-HER2 therapeutics]. | 2013 | Gan To Kagaku Ryoho | pmid:23306913 |
| Ono Y et al. | Antitumor and cytocidal activities of a newly isolated benzenoid ansamycin, macbecin I. | 1982 | Gan | pmid:6186564 |
| Tsuruo T et al. | Establishment and properties of vincristine-resistant human myelogenous leukemia K562. | 1983 | Gan | pmid:6580255 |
| Lianos GD and Roukos DH | From linear 'dogma' and trastuzumab-emtansine to future transcriptional circuitry-based drug discovery for breast cancer. | 2014 | Future Oncol | pmid:24490597 |
| Moore KN et al. | FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. | 2018 | Future Oncol | pmid:29424243 |
| Doroshow DB and LoRusso PM | Trastuzumab emtansine: determining its role in management of HER2+ breast cancer. | 2018 | Future Oncol | pmid:29214842 |
| Fabi A et al. | Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? | 2017 | Future Oncol | pmid:29182361 |
| Moore KN et al. | A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. | 2018 | Future Oncol | pmid:29098867 |
| Peddi PF and Hurvitz SA | Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. | 2013 | Future Oncol | pmid:23469968 |
| Chu YW and Polson A | Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia. | 2013 | Future Oncol | pmid:23469971 |
| Bighin C et al. | Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients. | 2013 | Future Oncol | pmid:23837759 |
| Berdeja JG | Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma. | 2014 | Front Biosci (Landmark Ed) | pmid:24389179 |
| Eckelmann D et al. | Spatial profiling of maytansine during the germination process of Maytenus senegalensis seeds. | 2017 | Fitoterapia | pmid:28385670 |
| Eckelmann D et al. | Occurrence and spatial distribution of maytansinoids in Putterlickia pyracantha, an unexplored resource of anticancer compounds. | 2016 | Fitoterapia | pmid:27521896 |
| Yap LW et al. | Role of CD56 in Normal Kidney Development and Wilms Tumorigenesis. | 2017 | Fetal Pediatr Pathol | pmid:27935326 |
| Bhattacharyya B and Wolff J | Maytansine binding to the vinblastine sites of tubulin. | 1977 | FEBS Lett. | pmid:852577 |
| Miranda Romero P and MarÃn Gil R | Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report. | 2015 | Farm Hosp | pmid:26005893 |
| Sapra P et al. | Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates. | 2013 | Expert Rev Clin Pharmacol | pmid:23978126 |